CN110669015A - Preparation method of FGFR inhibitor - Google Patents
Preparation method of FGFR inhibitor Download PDFInfo
- Publication number
- CN110669015A CN110669015A CN201810719247.7A CN201810719247A CN110669015A CN 110669015 A CN110669015 A CN 110669015A CN 201810719247 A CN201810719247 A CN 201810719247A CN 110669015 A CN110669015 A CN 110669015A
- Authority
- CN
- China
- Prior art keywords
- group
- compound
- formula
- reacting
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to FGFR inhibitor of formula (R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h]The invention discloses a synthetic method of quinazoline-2-amine (I), belonging to the field of organic synthesis.
Description
Technical Field
The invention relates to a novel synthesis method of FGFR inhibitor (R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h ] quinazoline-2-amine (I).
Background
The Fibroblast Growth Factor Receptor (FGFR) family is composed of four members (FGFR1, FGFR2, FGFR3 and FGFR4), which belong to the kinase family of receptor tyrosine kinases, with FGF binding leading to FGFR dimerization followed by receptor autophosphorylation and activation of downstream signaling pathways. Receptor activation is sufficient to restore and activate specific downstream signaling partners involved in the regulation of diverse processes such as cell growth, cell metabolism, and cell survival. Thus, FGF/FGFR signaling pathways have a multi-effect role in many biological processes critical for tumor cell proliferation, migration, infiltration, angiogenesis, and cell.
At present, a plurality of FGFR inhibitors are in clinical stage, wherein Derazaniib, the chemical name of (R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-amine (I) is in clinical stage III, and is used for drugs for potential treatment of solid tumors such as cholangiocarcinoma, and a synthetic method of the process is disclosed in a patent application WO 2017106639.
Firstly, converting (R) -4- (2-fluorophenyl) -3, 4-dihydronaphthalene-1 (2H) -ketone (compound A) into (R, E) -2- ((dimethylamino) methylene) -4- (2-fluorophenyl) -3, 4-dihydronaphthalene-1 (2H) -ketone (compound B), then reacting with 3- (2-hydroxyethyl) phenylguanidine methanesulfonate (compound C) to obtain (R) -2- (3- ((6- (2-fluorophenyl) -5, 6-dihydrobenzo [ H ] quinazolin-2-yl) amino) phenyl) ethanol (compound D), then reacting with methanesulfonyl chloride to obtain (R) -2- (3- ((6- (2-fluorophenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-yl) amino) phenyl) ethanol mesylate (compound E) is treated with 2-methoxyethylamine to obtain (R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-amine (compound I). The method adopts a linear synthesis process, and the use efficiency of the raw material chiral compound A is not high; in addition, the synthesis of the compound C in WO2010078421 is complicated and difficult to purify, and the industrial production of the target compound is greatly influenced.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide a synthesis method for preparing Derazatinib, (R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-amine (I) or pharmaceutically acceptable salts thereof:
wherein:
(i) reacting a compound of formula (IA) or a salt thereof with a compound of formula (IB) in a solvent to give a compound of formula (IC);
(ii) optionally removing the protecting group PG from the compound of formula (IC) to obtain a compound of formula (I);
wherein: PG is selected from a hydrogen atom or an N protecting group.
Preferably, PG is selected from a hydrogen atom, a formyl group, an acetyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a benzyloxycarbonyl group, a tert-butoxycarbonyl group, an allyloxycarbonyl group, a benzyl group, a p-methoxybenzyl group or a 2- (trimethylsilyl) ethoxymethyl chloride.
More preferably, PG is selected from benzyloxycarbonyl.
In a preferred embodiment of the present invention, a process for preparing a compound of formula (I), wherein in step (I):
the feeding molar ratio of the general formula (IA) to the general formula (IB) is 3: 1-1: 3, preferably the ratio is 2: 1-1: 1, and more preferably the ratio is 1.4: 1;
the solvent is selected from methanol, ethanol, isopropanol, n-butanol, ethyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, and methyl tert-butylThe solvent is a single or mixed solvent of an ether, dioxane, acetonitrile, N-dimethylformamide, N-dimethylacetamide and N-methylpyrrolidone, preferably a mixed solvent of ethanol and 2-methyltetrahydrofuran, and more preferably VEthanol：V(2-methyltetrahydrofuran)1: 2; and the number of the first and second electrodes,
the reaction temperature is 0-150 ℃, and the preferable reaction temperature is 80 ℃.
In a preferred embodiment of the present invention, a process for preparing a compound of formula (I), wherein in step (ii):
reducing the compound of the general formula (IC) in the presence of palladium on carbon under hydrogen condition;
the reaction temperature is 0-150 ℃, and the preferable reaction temperature is 25 ℃;
the solvent is selected from methanol, ethanol, isopropanol, N-butanol, ethyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, methyl tert-butyl ether, dioxane, acetonitrile, N-dimethylformamide, N-dimethylacetamide and N-methylpyrrolidone, or their mixture, preferably tetrahydrofuran;
wherein: PG is selected from the group consisting of a hydrogen atom, a formyl group, an acetyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a benzyloxycarbonyl group, a tert-butoxycarbonyl group, an allyloxycarbonyl group, a benzyl group, a p-methoxybenzyl group and a 2- (trimethylsilyl) ethoxymethyl chloride.
In a preferred embodiment of the present invention, the process for preparing a compound of formula (I), wherein the reaction conditions for removing the protecting group in step (ii) are selected from the group consisting of:
carrying out hydrogen reduction reaction under the catalysis of palladium carbon;
carrying out hydrogen reduction reaction under the catalysis of palladium carbon and in the presence of ammonia gas;
carrying out hydrogen reduction reaction under the catalysis of palladium carbon and in the presence of acetic acid;
carrying out hydrogen reduction reaction under the catalysis of palladium carbon and in the presence of potassium acetate;
reacting trimethyl iodosilane in acetonitrile;
reacting trimethyl bromosilane in trifluoroacetic acid and methyl phenyl sulfide;
reacting boron tribromide in dichloromethane;
reacting boron trichloride in dichloromethane;
reacting 6N hydrochloric acid under reflux conditions;
reacting lithium borohydride in methanol or ethanol;
reacting sodium borohydride and trimethylchlorosilane in methanol or ethanol;
reacting 40% potassium hydroxide in methanol and water;
reacting boron trifluoride diethyl etherate in ethanethiol and dichloromethane;
reacting boron trifluoride diethyl etherate in dimethyl sulfide and dichloromethane;
the preferred reaction conditions are: and (3) carrying out hydrogen reduction reaction in the presence of palladium carbon.
Wherein: PG is selected from benzyloxycarbonyl.
A synthetic process for the preparation of a compound of formula (IA) or a salt thereof, said process comprising:
(a) reacting the compound of the general formula (Ia) with the compound of the general formula (Ib) in a solvent to obtain a compound of a general formula (Ic);
(b) the compound of the general formula (Ic) is further deprotected to give a compound of the general formula (IA) or a salt thereof.
Wherein:
g is a protecting group for N, preferably selected from formyl, acetyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, tert-butoxycarbonyl or allyloxycarbonyl; preferably tert-butoxycarbonyl;
PG is selected from a hydrogen atom or a protective group for N, preferably from a hydrogen atom, formyl group, acetyl group, methoxycarbonyl group, ethoxycarbonyl group, benzyloxycarbonyl group, tert-butoxycarbonyl group, allyloxycarbonyl group, benzyl group, p-methoxybenzyl group or 2- (trimethylsilyl) ethoxymethyl group, preferably benzyloxycarbonyl group.
A synthetic process for the preparation of a compound of formula (IA) or a salt thereof, wherein in step (a):
the molar ratio of formula (Ia) to formula (Ib) is 1:2 to 2:1, preferably the ratio is 1: 1;
the reaction temperature is 0-120 ℃, and the preferable reaction temperature is 50 ℃;
the reaction solvent is selected from methanol, ethanol, isopropanol, N-butanol, ethyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, methyl tert-butyl ether, dioxane, acetonitrile, N-dimethylformamide, N-dimethylacetamide or N-methylpyrrolidone or a mixed solvent; preferably, the reaction solvent is 2-methyltetrahydrofuran.
A synthetic process for the preparation of a compound of formula (IA) or a salt thereof, wherein the deprotection conditions in step (b) are selected from the group consisting of:
reacting the compound of the general formula (Ic) with hydrochloric acid in a methanol solvent;
reacting the compound of the general formula (Ic) with trifluoroacetic acid in a dichloromethane solvent;
reacting the compound of formula (Ic) with methanesulfonic acid in dichloromethane; alternatively, the first and second electrodes may be,
reacting the compound of formula (Ic) with p-toluenesulfonic acid monohydrate in tetrahydrofuran;
the preferred reaction conditions are: the compound of formula (Ic) is reacted with p-toluenesulfonic acid monohydrate in tetrahydrofuran.
A synthetic method for preparing a compound represented by the general formula (IA) or a salt thereof, wherein the salt of the general formula (IA) is selected from hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, trifluoromethanesulfonate, p-toluenesulfonate or sulfonate.
A compound of formula (IA) or a salt thereof, which is an intermediate in the preparation of a compound of formula (I):
wherein:
PG is selected from a hydrogen atom or an N protecting group;
PG is preferably selected from a hydrogen atom, a formyl group, an acetyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a benzyloxycarbonyl group, a tert-butoxycarbonyl group, an allyloxycarbonyl group, a benzyl group, a p-methoxybenzyl group or a 2- (trimethylsilyl) ethoxymethyl chloride; more preferably a benzyloxycarbonyl group.
Wherein the salt is selected from the group consisting of hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, triflate, p-toluenesulfonate, or sulfonate.
The invention simply and efficiently prepares guanidine compounds of general formula (IA) and salts thereof, and reacts with compound A ((R) -4- (2-fluorophenyl) -3, 4-dihydronaphthalene-1 (2H) -ketone) to synthesize the compound of formula (I). Compared with the preparation method of the compound C in WO2010078421, the synthesis operation of the compound (IA) and the salt thereof in the general formula is convenient and easy to purify, and meanwhile, the efficiency is remarkably improved due to the adoption of a convergent synthesis strategy.
Detailed description of the invention
Unless stated to the contrary, some of the terms used in the specification and claims of the present invention are defined as follows:
"formyl" refers to-C (═ O) CH3；
"acetyl" means-C (═ O) CH2CH3；
"Methoxycarbonyl" means-C (═ O) OCH3；
"ethoxycarbonyl" refers to-C (═ O) OCH2CH3；
"benzyloxycarbonyl" means-C (═ O) OCH2-a phenyl group;
"tert-butoxycarbonyl" refers to-C (═ O) OC (CH)3)3；
"allyloxycarbonyl" means-C (═ O) OCH2CH＝CH2；
"benzyl" means-CH2-a phenyl group;
"P-methoxybenzyl" refers to p-OCH3-a benzyl group;
"2- (trimethylsilyl) ethoxymethyl" means; -CH2OCH2CH2Si(CH3)3。
"Boc" refers to tert-butoxycarbonyl;
"Cbz" refers to benzyloxycarbonyl.
In the invention, the compound A and the compound 1h represent the compound with the same structure; compound B, compound of formula (IB) and compound 1i characterize compounds of the same structure.
Detailed Description
The present invention will be further described with reference to the following examples, which are not intended to limit the scope of the present invention.
Examples
The examples show the preparation of representative compounds represented by formula (I) and the associated structural identification data. It must be noted that the following examples are intended to illustrate the invention and are not intended to limit the invention.1The H NMR spectrum was obtained using a Bruker instrument (400MHz) and the chemical shifts were expressed in ppm. Tetramethylsilane internal standard (0.00ppm) was used.1Method for H NMR expression: s is singlet, d is doublet, t is triplet, m is multiplet, br is broadened, dd is doublet of doublet, dt is doublet of triplet. If a coupling constant is provided, it is in Hz.
The mass spectrum is measured by an LC/MS instrument, and the ionization mode can be ESI or APCI.
The thin layer chromatography silica gel plate adopts HSGF254 of tobacco yellow sea or GF254 of Qingdao, the specification of the silica gel plate used by Thin Layer Chromatography (TLC) is 0.15 mm-0.2 mm, and the specification of the thin layer chromatography separation and purification product is 0.4 mm-0.5 mm.
The column chromatography generally uses 200-300 mesh silica gel of the Tibet Huanghai silica gel as a carrier.
In the following examples, all temperatures are in degrees Celsius unless otherwise indicated, and unless otherwise indicated, the various starting materials and reagents are commercially available or synthesized according to known methods, and none of the commercially available materials and reagents are used without further purification, and unless otherwise indicated, commercially available manufacturers include, but are not limited to, Aldrich Chemical Company, ABCR GmbH & Co. KG, Acros Organics, Prov Chemical science Inc. and Sci Chemical science Inc., and the like.
CD3OD: deuterated methanol.
CDCl3: deuterated chloroform.
DMSO-d6: deuterated dimethyl sulfoxide.
The argon atmosphere means that the reaction flask is connected with an argon balloon having a volume of about 1L.
In the examples, the solution in the reaction is an aqueous solution unless otherwise specified.
Purifying the compound by silica gel column chromatography using an eluent system selected from the group consisting of: a: petroleum ether and ethyl acetate systems; b: dichloromethane and methanol systems; c: dichloromethane: ethyl acetate; d: petroleum ether: a dichloromethane system; the volume ratio of the solvent is different according to the polarity of the compound, and a small amount of acidic or basic reagent such as acetic acid or triethylamine can be added for adjustment.
Example 1
(R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-amine
First step of
3-Nitrophenyl Ethyl methane sulfonate
2- (3-Nitrophenyl) ethan-1-ol 1a (100g, 598mmol) was dissolved in 1L of dichloromethane, triethylamine (121g, 1.2mol,2eq) was added with stirring, methanesulfonyl chloride (137g, 1.2mol,2eq) was added dropwise to the reaction solution under cooling in an ice bath, and the reaction was carried out at room temperature for 1 hour after the addition. 500mL of water was added, the layers were separated, the aqueous phase was extracted with dichloromethane (500mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 3-nitrophenylethyl methanesulfonate 1b (110g,448mmol, yellow liquid), yield: 75 percent.
1H NMR(400MHz,CDCl3)δ8.07-8.21(m,2H),7.56-7.65(m,1H),7.49-7.56(m,1H),4.48(t,J＝6.60Hz,2H),3.19(t,J＝6.60Hz,2H),2.96(s,3H)
Second step of
2-methoxy-N- (3-nitrophenylethyl) ethan-1-amine
3-Nitrophenyl ethyl methanesulfonate 1b (100g,407mmol) was dissolved in 500mL of 2-methyltetrahydrofuran, and methoxyethylamine (220g, 2.85mol,7eq) was added with stirring to react at 70 ℃ for 3 hours. The reaction solution was concentrated under reduced pressure to give 2-methoxy-N- (3-nitrophenylethyl) ethan-1-amine 1c (92g,407mmol, yellow liquid), yield: 100 percent.
1H NMR(400MHz,CDCl3)δ8.01-8.15(m,2H),7.58(m,1H),7.40-7.52(m,1H),3.44-3.59(m,2H),3.35(s,3H),2.96(m,3H),2.77-2.89(m,2H),2.36(br.s.,1H).
The third step
(2-methoxyethyl) (3-nitrophenylethyl) carbamic acid benzyl ester
2-methoxy-N- (3-nitrophenylethyl) ethan-1-amine 1c (92g,407 mmol) was dissolved in 800mL of dichloromethane, triethylamine (83g, 815mmol,2eq) was added with stirring, and benzyl chloroformate (105g,615mmol,1.5eq) was added dropwise with cooling on an ice bath and reacted at room temperature for 2 hours. To the reaction mixture was added 200mL of water, extracted with dichloromethane (200mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give benzyl (2-methoxyethyl) (3-nitrophenylethyl) carbamate 1d (147g, 407mmol, yellow liquid), yield: 100 percent.
1H NMR(400MHz,DMSO-d6)δ7.48-7.77(m,2H),7.18-7.45(m,5H),4.85-5.18(m,2H),3.48-3.65(m,2H),3.33-3.49(m,4H),3.13-3.32(m,3H),2.95(d,J＝7.34Hz,2H).
The fourth step
(3-Aminophenylethyl) (2-methoxyethyl) carbamic acid benzyl ester
Dissolving (2-methoxyethyl) (3-nitrophenylethyl) benzyl carbamate 1d (147g, 407mmol) in 1L of ethanol, adding 1L of saturated ammonium chloride solution while stirring, adding zinc powder (100g, 1.54mol,3.8eq) in portions while cooling in an ice bath, and after the dropwise addition is finished, heating to reflux for 2 hours. The reaction solution was concentrated under reduced pressure to remove ethanol, the aqueous phase was extracted with ethyl acetate (500mL × 4), the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to give benzyl (3-aminophenylethyl) (2-methoxyethyl) carbamate 1e (100g,304mmol, yellow liquid), yield: 74 percent.
1H NMR(400MHz,CDCl3)δ7.25-7.57(m,5H),6.96-7.16(m,1H),6.30-6.76(m,3H),5.02-5.27(m,2H),3.18-3.66(m,9H),3.00(br,2H),2.66-2.85(m,2H).
LCMS：M+H+＝329.5M+Na+＝351.5
The fifth step
N- [2- [3- [ (N, N' -bis (tert-butoxycarbonyl) guanidino) phenyl ] ethyl ] -N- (2-methoxyethyl) carbamic acid benzyl ester
Benzyl (3-aminophenylethyl) (2-methoxyethyl) carbamate 1e (100g,304 mmol), N, N '-di-tert-butoxycarbonyl-1H-1-guanidinopyrazole (95g,306mmol,1eq) were dissolved in 800mL of 2-methyltetrahydrofuran, reacted at 50 ℃ for 3 hours, and quenched by addition of N, N' -dimethylethylenediamine. Concentrating the reaction solution under reduced pressure, and purifying the residue by silica gel column chromatography to obtain
Benzyl N- [2- [3- [ (N, N' -bis (tert-butoxycarbonyl) guanidino) phenyl ] ethyl ] -N- (2-methoxyethyl) carbamate 1f (147g,257mmol, yellow solid), yield: 84 percent.
1H NMR(400MHz,CDCl3)δ11.68(br.s.,1H),10.13-10.55(m,1H),7.48-7.67(m,1H),7.15-7.48(m,7H),6.75-7.06(m,1H),5.14(d,J＝9.78Hz,2H),3.73(q,J＝7.09Hz,1H),3.20-3.64(m,8H),2.70-2.99(m,2H),1.37-1.73(m,18H)
The sixth step
(3-guanidinophenylethyl) (2-methoxyethyl) carbamic acid benzyl ester
Benzyl N- [2- [3- [ (N, N' -bis (tert-butoxycarbonyl) guanidino) amino ] phenyl ] ethyl ] -N- (2-methoxyethyl) carbamate 1f (147g,257mmol) was dissolved in 2.2L of tetrahydrofuran, and p-toluenesulfonic acid monohydrate (300g,1.57mol,6.0eq) was added with stirring and reacted at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give benzyl (3-guanidinophenylethyl) (2-methoxyethyl) carbamate 1g (95g,257mmol, brown solid), yield: 100 percent.
1H NMR(400MHz,CDCl3)δ7.76(s,1H),7.08-7.44(m,6H),6.88-7.07(m,2H),6.80(br,4H),4.85-5.13(m,2H),3.14-3.70(m,7H),2.66-2.93(m,2H),2.35(s,2H)
LCMS：M+H+＝371.3
Seventh step
(R, E) -2- ((dimethylamino) methylene) -4- (2-fluorophenyl) -3, 4-dihydronaphthalen-1 (2H) -one
(R) -4- (2-fluorophenyl) -3, 4-dihydronaphthalen-1 (2H) -one 1H (50g,208mmol) was dissolved in 100mL DMF-DMA and stirred at 80 ℃ overnight. After the reaction solution was cooled, 1L of petroleum ether was added, a large amount of solid was precipitated, the solid was filtered, washed with petroleum ether (200mL × 2), dried to give (R, E) -2- ((dimethylamino) methylene) -4- (2-fluorophenyl) -3, 4-dihydronaphthalen-1 (2H) -one 1i (50g,169mmol, yellow solid), the mother liquor was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 1i (5g,17mmol, yellow solid) in yield: 89 percent.
1H NMR(400MHz,DMSO-d6)δ7.92(dd,J＝7.34,1.47Hz,1H),7.52-7.64(m,1H),7.32-7.46(m,2H),7.17-7.33(m,2H),7.05-7.15(m,1H),6.84-6.96(m,2H),4.42-4.53(m,1H),3.10-3.29(m,2H),3.02(s,6H)
Eighth step
Benzyl (R) - (3- ((6- (2-fluorophenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-yl) amino) phenethyl) (2-methoxyethyl) carbamate
1g (95g,257mmol,1.4eq) of benzyl (3-guanidinophenylethyl) (2-methoxyethyl) carbamate is dissolved in 400mL of ethanol and 800mL of 2-methyltetrahydrofuran solution, sodium ethoxide (8.7g,128mmol,0.75eq), (R, E) -2- ((dimethylamino) methylene) -4- (2-fluorophenyl) -3, 4-dihydronaphthalen-1 (2H) -one 1i (55g, 186mmol, 1.0eq) is added successively under argon protection and reacted at 80 ℃ overnight. Celite was filtered, the insoluble material was washed with a little ethyl acetate, and the filtrate was concentrated to silica gel column chromatography to purify (R) - (3- ((6- (2-fluorophenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-yl) amino) phenethyl) (2-methoxyethyl) carbamic acid benzyl ester 1j (70g, 116mmol, light yellow solid), yield: 62 percent.
1HNMR(400MHz,CDCl3)δ8.35-8.55(m,1H),8.17(br.s.,1H),7.15-7.70(m,12H),7.02-7.14(m,2H),6.70-7.00(m,3H),5.05-5.24(m,2H),4.70(t,J＝6.48Hz,1H),3.50-3.69(m,3H),3.26-3.50(m,6H),3.07-3.26(m,2H),2.78-3.02(m,2H)
LC-MS：M+H+＝603.6
The ninth step
(R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-amine
Benzyl (R) - (3- ((6- (2-fluorophenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-yl) amino) phenethyl) (2-methoxyethyl) carbamate 1j (70g, 116mmol) was dissolved in 700mL tetrahydrofuran and palladium on carbon (7g, 10% W/W,6.6mmol,0.57eq) was added. The reaction was carried out overnight at room temperature with hydrogen substitution three times. Palladium on carbon was removed by filtration through celite and purified by silica gel column chromatography to give the product (R) -6- (2-fluorophenyl) -N- (3- (2- ((2-methoxyethyl) amino) ethyl) phenyl) -5, 6-dihydrobenzo [ h ] quinazolin-2-amine (I) (40g, 85mmol, off-white solid) yield: 73 percent.
1H NMR(400MHz,CDCl3)δ2.15(br.s.,1H)2.84-2.94(m,4H)2.96-3.04(m,2H)3.17(qd,J＝15.36,6.48Hz,2H)3.35(s,3H)3.53(t,J＝5.14Hz,2H)4.69(t,J＝6.60Hz,1H)6.77(t,J＝7.70Hz,1H)6.88-6.98(m,2H)7.04-7.14(m,2H)7.16-7.25(m,2H)7.31(t,J＝7.82Hz,1H)7.38-7.51(m,2H)7.58(s,1H)7.63(d,J＝8.07Hz,1H)8.17(s,1H)8.44(d,J＝7.58Hz,1H)LCMS：M+H+＝469.5(M+2H+)/2＝235.1
HPLC：99.27％
ee：>98％
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (12)
1. A synthetic process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, said process comprising:
wherein:
(i) reacting a compound of formula (IA) or a salt thereof with a compound of formula (IB) in a solvent to give a compound of formula (IC);
(ii) optionally removing the protecting group PG from the compound of formula (IC) to obtain a compound of formula (I);
wherein: PG is selected from a hydrogen atom or an N protecting group.
2. The production process according to claim 1, wherein PG is selected from the group consisting of a hydrogen atom, a formyl group, an acetyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a benzyloxycarbonyl group, a tert-butoxycarbonyl group, an allyloxycarbonyl group, a benzyl group, a p-methoxybenzyl group and a 2- (trimethylsilyl) ethoxymethyl group.
3. The method according to claim 1, wherein PG is selected from benzyloxycarbonyl.
4. The production method according to claim 1, wherein in step (i):
the feeding molar ratio of the general formula (IA) to the general formula (IB) is 3: 1-1: 3, preferably the ratio is 2: 1-1: 1, and more preferably the ratio is 1.4: 1;
the solvent is selected from methanol, ethanol, isopropanol, n-butanol, ethyl acetate, tetrahydrofuran, and 2-methyltetra-ethylTetrahydrofuran, methyl tert-butyl ether, dioxane, acetonitrile, N-dimethylformamide, N-dimethylacetamide and N-methylpyrrolidone, preferably a mixed solvent of ethanol and 2-methyltetrahydrofuran, more preferably a mixed solvent of ethanol and 2-methyltetrahydrofuran, wherein V isEthanol：V(2-methyltetrahydrofuran)＝1:2；
The reaction temperature is 0-150 ℃, and the preferable reaction temperature is 80 ℃.
5. The production method according to claim 2, wherein in step (ii):
reducing the compound of the general formula (IC) in the presence of palladium on carbon under hydrogen condition;
the reaction temperature is 0-150 ℃, and the preferable reaction temperature is 25 ℃;
the solvent is selected from methanol, ethanol, isopropanol, N-butanol, ethyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, methyl tert-butyl ether, dioxane, acetonitrile, N-dimethylformamide, N-dimethylacetamide and N-methylpyrrolidone, or their mixture, preferably tetrahydrofuran.
6. The production process according to claim 3, wherein the reaction conditions for deprotecting in step (ii) are selected from:
carrying out hydrogen reduction reaction under the catalysis of palladium carbon;
carrying out hydrogen reduction reaction under the catalysis of palladium carbon and in the presence of ammonia gas;
carrying out hydrogen reduction reaction under the catalysis of palladium carbon and in the presence of acetic acid;
carrying out hydrogen reduction reaction under the catalysis of palladium carbon and in the presence of potassium acetate;
reacting trimethyl iodosilane in acetonitrile;
reacting trimethyl bromosilane in trifluoroacetic acid and methyl phenyl sulfide;
reacting boron tribromide in dichloromethane;
reacting boron trichloride in dichloromethane;
reacting 6N hydrochloric acid under reflux conditions;
reacting lithium borohydride in methanol or ethanol;
reacting sodium borohydride and trimethylchlorosilane in methanol or ethanol;
reacting 40% potassium hydroxide in methanol and water;
reacting boron trifluoride diethyl etherate in ethanethiol and dichloromethane; alternatively, the first and second electrodes may be,
boron trifluoride diethyl etherate is reacted in dimethyl sulfide and dichloromethane.
The preferred reaction conditions are: and (3) carrying out hydrogen reduction reaction in the presence of palladium carbon.
7. A synthetic process for the preparation of a compound of formula (IA) or a salt thereof, said process comprising:
(a) reacting the compound of the general formula (Ia) with the compound of the general formula (Ib) in a solvent to obtain a compound of a general formula (Ic);
(b) the compound of the general formula (Ic) is further deprotected to give a compound of the general formula (IA) or a salt thereof.
Wherein:
g is a protecting group for N, preferably selected from formyl, acetyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, tert-butoxycarbonyl or allyloxycarbonyl; preferably tert-butoxycarbonyl;
PG is selected from a hydrogen atom or a protective group for N, preferably from a hydrogen atom, formyl group, acetyl group, methoxycarbonyl group, ethoxycarbonyl group, benzyloxycarbonyl group, tert-butoxycarbonyl group, allyloxycarbonyl group, benzyl group, p-methoxybenzyl group or 2- (trimethylsilyl) ethoxymethyl group, preferably benzyloxycarbonyl group.
8. The method according to claim 7, wherein the step (a):
the molar ratio of formula (Ia) to formula (Ib) is 1:2 to 2:1, preferably the ratio is 1: 1;
the reaction temperature is 0-120 ℃, and the preferable reaction temperature is 50 ℃;
the reaction solvent is selected from methanol, ethanol, isopropanol, N-butanol, ethyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, methyl tert-butyl ether, dioxane, acetonitrile, N-dimethylformamide, N-dimethylacetamide or N-methylpyrrolidone or a mixed solvent; preferably, the reaction solvent is 2-methyltetrahydrofuran.
9. The process according to claim 7, wherein the conditions for removing the protecting group in the step (b) are selected from the group consisting of:
reacting the compound of the general formula (Ic) with hydrochloric acid in a methanol solvent;
reacting the compound of the general formula (Ic) with trifluoroacetic acid in a dichloromethane solvent;
reacting the compound of formula (Ic) with methanesulfonic acid in dichloromethane; alternatively, the first and second electrodes may be,
reacting the compound of formula (Ic) with p-toluenesulfonic acid monohydrate in tetrahydrofuran;
the preferred reaction conditions are: the compound of formula (Ic) is reacted with p-toluenesulfonic acid monohydrate in tetrahydrofuran.
10. The process according to claim 7, wherein the salt of formula (IA) is selected from the group consisting of hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, triflate, p-toluenesulfonate and sulfonate.
11. A compound of formula (IA) or a salt thereof, which is an intermediate in the preparation of a compound of formula (I):
wherein:
PG is selected from a hydrogen atom or an N protecting group;
PG is preferably selected from a hydrogen atom, a formyl group, an acetyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a benzyloxycarbonyl group, a tert-butoxycarbonyl group, an allyloxycarbonyl group, a benzyl group, a p-methoxybenzyl group or a 2- (trimethylsilyl) ethoxymethyl chloride; more preferably a benzyloxycarbonyl group.
12. A compound or salt thereof according to claim 11 wherein the salt is selected from the group consisting of hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, triflate, p-toluenesulfonate and sulfonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810719247.7A CN110669015A (en) | 2018-07-03 | 2018-07-03 | Preparation method of FGFR inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810719247.7A CN110669015A (en) | 2018-07-03 | 2018-07-03 | Preparation method of FGFR inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110669015A true CN110669015A (en) | 2020-01-10 |
Family
ID=69065824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810719247.7A Pending CN110669015A (en) | 2018-07-03 | 2018-07-03 | Preparation method of FGFR inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110669015A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761655A (en) * | 2003-01-27 | 2006-04-19 | 安斯泰来制药有限公司 | Thiazole derivatives and their use as VAP-1 inhibitors |
| CN102325755A (en) * | 2008-12-30 | 2012-01-18 | 阿奎利公司 | Substituted 5,6-dihydro-6-phenyl benzo [F] isoquinoline 99.9-2-amine compound |
| WO2017106639A1 (en) * | 2015-12-17 | 2017-06-22 | Arqule, Inc. | Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine |
| CN107074769A (en) * | 2014-09-05 | 2017-08-18 | 艾科尔公司 | composition and method for treating proliferative disorders |
-
2018
- 2018-07-03 CN CN201810719247.7A patent/CN110669015A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1761655A (en) * | 2003-01-27 | 2006-04-19 | 安斯泰来制药有限公司 | Thiazole derivatives and their use as VAP-1 inhibitors |
| CN102325755A (en) * | 2008-12-30 | 2012-01-18 | 阿奎利公司 | Substituted 5,6-dihydro-6-phenyl benzo [F] isoquinoline 99.9-2-amine compound |
| CN107074769A (en) * | 2014-09-05 | 2017-08-18 | 艾科尔公司 | composition and method for treating proliferative disorders |
| WO2017106639A1 (en) * | 2015-12-17 | 2017-06-22 | Arqule, Inc. | Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine |
Non-Patent Citations (2)
| Title |
|---|
| ELENA BEJAN: "Enaminones in the Synthesis of New Polyaza Heterocycles", 《EUR. J. ORG. CHEM.》 * |
| 刘鹰翔: "《药物合成反应（新世纪第二版）》", 31 August 2017, 中国中医药出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1491542B1 (en) | Intermediate compounds for the preparation of imidazo-pyridine-derivatives | |
| US20100292480A1 (en) | Process and intermediates for preparing integrase inhibitors | |
| EP4043468A1 (en) | Preparation method for glufosinate ammonium | |
| EP2451786B1 (en) | Improved process for the preparation of ambrisentan and novel intermediates thereof | |
| CA2646795A1 (en) | Process for the preparation of bosentan | |
| KR20190013555A (en) | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | |
| EP2483246B1 (en) | Process for preparing biphenyl imidazole compounds | |
| CN110669015A (en) | Preparation method of FGFR inhibitor | |
| BG63721B1 (en) | Method for the preparation of valacyclovir and relevant intermediate products | |
| EP0351126B1 (en) | Process for the production of 02,2'-anhydro-1-(beta-D-arabinofuranosyl)thymine | |
| WO2012011939A2 (en) | Synthesis of cyclopentaquinazolines | |
| SU950188A3 (en) | Process for producing derivatives of 4(5)-mercaptomethylimidazoles | |
| US8093384B2 (en) | Processes for the preparation of alfuzosin | |
| EP3564219B1 (en) | Process for preparing oxadiazacyclo compound and use thereof | |
| CN111527067B (en) | Process for the preparation of 1- [5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl ] -N-methylmethylamine monofumarate | |
| CN112135820B (en) | Novel process for preparing diaminopyrimidine derivatives or acid addition salts thereof | |
| US20230250041A1 (en) | Method and intermediate compounds for the preparation of menaquinone mk-7 | |
| CN109928968B (en) | Intermediate for preparing anticancer medicine | |
| KR100869165B1 (en) | Process for preparing meropenem | |
| CN110746459A (en) | Preparation method of Avramide | |
| US4897495A (en) | Process for the preparation of pyrrolizine derivatives | |
| CN118076620A (en) | Process for producing 2' -modified pyrimidine nucleoside | |
| WO2022259222A1 (en) | Process for preparing an erk inhibitor | |
| EP4219443A1 (en) | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist | |
| CN118005693A (en) | Preparation method of tenofovir alafenamide fumarate impurity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200110 |
|
| WD01 | Invention patent application deemed withdrawn after publication |